These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 29298867

  • 1. Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis.
    Richards DB, Cookson LM, Barton SV, Liefaard L, Lane T, Hutt DF, Ritter JM, Fontana M, Moon JC, Gillmore JD, Wechalekar A, Hawkins PN, Pepys MB.
    Sci Transl Med; 2018 Jan 03; 10(422):. PubMed ID: 29298867
    [Abstract] [Full Text] [Related]

  • 2. Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component.
    Richards DB, Cookson LM, Berges AC, Barton SV, Lane T, Ritter JM, Fontana M, Moon JC, Pinzani M, Gillmore JD, Hawkins PN, Pepys MB.
    N Engl J Med; 2015 Sep 17; 373(12):1106-14. PubMed ID: 26176329
    [Abstract] [Full Text] [Related]

  • 3. Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study.
    Wechalekar A, Antoni G, Al Azzam W, Bergström M, Biswas S, Chen C, Cheriyan J, Cleveland M, Cookson L, Galette P, Janiczek RL, Kwong RY, Lukas MA, Millns H, Richards D, Schneider I, Solomon SD, Sörensen J, Storey J, Thompson D, van Dongen G, Vugts DJ, Wall A, Wikström G, Falk RH.
    BMC Cardiovasc Disord; 2022 Feb 13; 22(1):49. PubMed ID: 35152886
    [Abstract] [Full Text] [Related]

  • 4. An observational, non-interventional study for the follow-up of patients with amyloidosis who received miridesap followed by dezamizumab in a phase 1 study.
    Richards D, Millns H, Cookson L, Lukas MA.
    Orphanet J Rare Dis; 2022 Jul 09; 17(1):259. PubMed ID: 35810311
    [Abstract] [Full Text] [Related]

  • 5. The Pentraxins 1975-2018: Serendipity, Diagnostics and Drugs.
    Pepys MB.
    Front Immunol; 2018 Jul 09; 9():2382. PubMed ID: 30459761
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits.
    Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA, Hutchinson WL, Mangione PP, Gallimore JR, Millar DJ, Minogue S, Dhillon AP, Taylor GW, Bradwell AR, Petrie A, Gillmore JD, Bellotti V, Botto M, Hawkins PN, Pepys MB.
    Nature; 2010 Nov 04; 468(7320):93-7. PubMed ID: 20962779
    [Abstract] [Full Text] [Related]

  • 8. Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis.
    Gillmore JD, Tennent GA, Hutchinson WL, Gallimore JR, Lachmann HJ, Goodman HJ, Offer M, Millar DJ, Petrie A, Hawkins PN, Pepys MB.
    Br J Haematol; 2010 Mar 04; 148(5):760-7. PubMed ID: 20064157
    [Abstract] [Full Text] [Related]

  • 9. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis.
    Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C, Hoffmann T, Jakob-Roetne R, Norcross RD, Kemp JA, Yamamura K, Suzuki M, Taylor GW, Murray S, Thompson D, Purvis A, Kolstoe S, Wood SP, Hawkins PN.
    Nature; 2002 May 16; 417(6886):254-9. PubMed ID: 12015594
    [Abstract] [Full Text] [Related]

  • 10. Pharmacological removal of serum amyloid P component from intracerebral plaques and cerebrovascular Aβ amyloid deposits in vivo.
    Al-Shawi R, Tennent GA, Millar DJ, Richard-Londt A, Brandner S, Werring DJ, Simons JP, Pepys MB.
    Open Biol; 2016 Feb 16; 6(2):150202. PubMed ID: 26842068
    [Abstract] [Full Text] [Related]

  • 11. Kinetic studies with iodine-123-labeled serum amyloid P component in patients with systemic AA and AL amyloidosis and assessment of clinical value.
    Jager PL, Hazenberg BP, Franssen EJ, Limburg PC, van Rijswijk MH, Piers DA.
    J Nucl Med; 1998 Apr 16; 39(4):699-706. PubMed ID: 9544684
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component.
    Hawkins PN, Lavender JP, Pepys MB.
    N Engl J Med; 1990 Aug 23; 323(8):508-13. PubMed ID: 2377176
    [Abstract] [Full Text] [Related]

  • 13. Randomized phase I trial HIV-CORE 003: Depletion of serum amyloid P component and immunogenicity of DNA vaccination against HIV-1.
    Borthwick NJ, Lane T, Moyo N, Crook A, Shim JM, Baines I, Wee EG, Hawkins PN, Gillmore JD, Hanke T, Pepys MB.
    PLoS One; 2018 Aug 23; 13(5):e0197299. PubMed ID: 29772028
    [Abstract] [Full Text] [Related]

  • 14. Prospective and serial study of primary amyloidosis with serum amyloid P component scintigraphy: from diagnosis to prognosis.
    Hachulla E, Maulin L, Deveaux M, Facon T, Blétry O, Vanhille P, Wechsler B, Godeau P, Levesque H, Hatron PY, Huglo D, Devulder B, Marchandise X.
    Am J Med; 1996 Jul 23; 101(1):77-87. PubMed ID: 8686719
    [Abstract] [Full Text] [Related]

  • 15. Metabolic studies of radioiodinated serum amyloid P component in normal subjects and patients with systemic amyloidosis.
    Hawkins PN, Wootton R, Pepys MB.
    J Clin Invest; 1990 Dec 23; 86(6):1862-9. PubMed ID: 2254450
    [Abstract] [Full Text] [Related]

  • 16. Monitoring systemic amyloidosis using MRI measurements of the extracellular volume fraction.
    Campbell-Washburn AE, Price AN, Ellmerich S, Simons JP, Al-Shawi R, Kalber TL, Ghatrora R, Hawkins PN, Moon JC, Ordidge RJ, Pepys MB, Lythgoe MF.
    Amyloid; 2013 Jun 23; 20(2):93-8. PubMed ID: 23621497
    [Abstract] [Full Text] [Related]

  • 17. Novel methods to determine complement activation in human serum induced by the complex of Dezamizumab and serum amyloid P.
    Ma J, Liu Q, White JR.
    J Biol Chem; 2021 Oct 23; 297(4):101136. PubMed ID: 34461096
    [Abstract] [Full Text] [Related]

  • 18. Drug targets for amyloidosis.
    Kolstoe SE, Wood SP.
    Biochem Soc Trans; 2010 Apr 23; 38(2):466-70. PubMed ID: 20298204
    [Abstract] [Full Text] [Related]

  • 19. Diagnostic performance and prognostic value of extravascular retention of 123I-labeled serum amyloid P component in systemic amyloidosis.
    Hazenberg BP, van Rijswijk MH, Lub-de Hooge MN, Vellenga E, Haagsma EB, Posthumus MD, Jager PL.
    J Nucl Med; 2007 Jun 23; 48(6):865-72. PubMed ID: 17504868
    [Abstract] [Full Text] [Related]

  • 20. Interaction of serum amyloid P component with hexanoyl bis(D-proline) (CPHPC).
    Kolstoe SE, Jenvey MC, Purvis A, Light ME, Thompson D, Hughes P, Pepys MB, Wood SP.
    Acta Crystallogr D Biol Crystallogr; 2014 Aug 23; 70(Pt 8):2232-40. PubMed ID: 25084341
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.